Modern Approaches to the Management of Children with Mucopolysaccharidosis Type I

This article presents modern data on epidemiology, etiology, and clinical manifestations of mucopolysaccharidosis (MPS) type I in children. MPS develops due to deficiency of particular lysosomal enzyme which determines the disease type. The article considers in details disease's pathogenesis and classification. Evidence-based approaches to diagnosis (differential diagnosis included) are covered, moreover, special attention is paid to pathogenetic, symptomatic, and surgical treatment of MPS.

1. Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123(1):19-29. doi: https://doi.org/10.1542/peds.2008-0416

2. Martins AM, Dualibi AP, Norato D, et al. Guidelines for the Management of Mucopolysaccharidosis Type I. J Pediatr. 2009;155(4 Suppl):S32-S46. doi: https://doi.org/10.1016/j.jpeds.2009.07.005

3. Thomas JA, Beck M, Clarke JTR, Cox GF Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis. 2010;33(4):421-427. doi: https://doi.org/10.1007/s10545-010-9113-7

4. Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94(7):872-877. doi: https://doi.org/10.1111/j.1651-2227.2005.tb02004.x

5. Leroy JG. Disorders of lysosomal enzymes: clinical phenotypes. In: Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects. Royce PM, Steinman B, eds. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2003.

6. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254. doi: https://doi.org/10.1001/jama.281.3.249

7. Neufeld E, Muenzer J. The mucopolysaccharidoses. In: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, et al., eds. 8th ed. New York, NY: McGraw-Hill; 2001. pp. 3421-3452.

8. Oussoren E, Keulemans J, van Diggelen OP, et al. Residual a-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients. Mol Genet Metab. 2013;109(4):377-381. doi: https://doi.org/10.1016/j.ymgme.2013.05.016

9. Beesley CE, Meaney CA, Greenland G, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet. 2001;109(5):503-511. doi: https://doi.org/10.1007/s004390100606

10. Aronovich EL, Pan D, Whitley CB. Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency. Am J Hum Genet. 1996;58(1):75-85.

11. De Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55. doi: https://doi.org/10.1186/1750-1172-6-55

12. Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase for treating mucopolysaccharidosis type I. Cochrane Database Sys Rev. 2016;4:CD009354. doi: https://doi.org/10.1002/14651858.CD009354.pub4

13. Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229-240. doi: https://doi.org/10.1542/peds.2007-3847

14. D'Aco K, Underhill L, Rangachari L, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr. 2012;171(6):911-919. doi: https://doi.org/10.1007/s00431-011-1644-x

15. Braunlin EA, Stauffer NR, Peters CH, et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2003;92(7):882-886. doi: https://doi.org/10.1016/s0002-9149(03)00909-3

16. Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr. 2013;162(2):375-380.e.1. doi: https://doi.org/10.1016/j.jpeds.2012.07.052

17. Dornelles AD, Artigalas O, da Silva AA, et al. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A system atic review and meta-analysis. PLoS One. 2017;12(8):e0184065. doi: https://doi.org/10.1371/journal.pone.0184065

18. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589-604. doi: https://doi.org/10.1590/S1415-47572010005000093

19. Eisengart JB, Rudser KD, Xue Y, et al. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med. 2018;20(11):1423-1429. doi: https://doi.org/10.1038/gim.2018.29

20. Arn P, Wraith JE, Underhill L, et al. Characterization of Surgical Procedures in Patients with Mucopolysaccharidosis Type I: Findings from the MPS I Registry. J Pediatr. 2009;154(6):859-864.e3. doi: https://doi.org/10.1016/j.jpeds.2008.12.024

21. Mironov SP, Kolesov SV, Pereverzev VS, et al. Surgical treatment of craniovertebral stenosis in patients with mucopolysaccharidosis type I, II, and VI. Hirurgia pozvonocnika = Spine Surgery. 2018;15(4):32-40. (In Russ). doi: https://doi.org/10.14531/2018.4.32-40

22. Williams N, Challoumas D, Eastwood DM. Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses? J Child Orthop. 2017;11(4):289-297. doi: https://doi.org/10.1302/1863-2548.11.170042

23. ATS statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med. 2002;166(1):111-117. doi: https://doi.org/10.1164/ajrccm.166.1.at1102

24. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-437. doi: https://doi.org/10.1111/all.12350

25. Demoly P, Adkinson NF, Brockow K, et al. International Consensus ondrug allergy. Allergy. 2014 Apr;69(4):420-37

26. Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):32. doi: https://doi.org/10.1186/s40413-015-0080-1

27. Bitencourt FH, Vieira TA, Steiner CE, et al. Medical Costs Related toEnzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study. Value Health Reg Issues. 2015;8:99-106. doi: https://doi.org/10.1016/j.vhri.2015.08.002

28. Vashakmadze ND. Mul'tidistsiplinarnye printsipy vedeniya detei s mukopolisakharidozami v povyshenii effektivnosti ikh diagnostiki i lecheniya. [abstract of dissertation]. Yekaterinburg; 2019. 47 p. (In Russ).

29. Berger KI, Fagondes SC, Giugliani R, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36(2):201-210. doi: https://doi.org/10.1007/s10545-012-9555-1

30. Scarpa M, Louren^o CM, Amartino H. Epilepsy in mucopolysaccharidosis disorders. Mol Genet Metab. 2017;122S:55-61. doi: https://doi.org/10.1016/j.ymgme.2017.10.006

31. Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34(6):1183-1197. doi: https://doi.org/10.1007/s10545-011-9359-8

32. Dornelles AD, Artigalas O, da Silva AA, et al. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis. PLoS One. 2017;12(8):e0184065. doi: https://doi.org/10.1371/journal.pone.0184065

33. Lin HY, Shih SC, Chuang CK, et al. Assessment of bone mineral density bydual energy x-ray absorptiometry in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2013;8:71. doi: https://doi.org/10.1186/1750-1172-8-71

34. Escolar ML, Jones SA, Shapiro EG, et al. Practical managementof behavioral problems in mucopolysaccharidoses disorders. Mol Genet Metab. 2017;122S:35-40. doi: https://doi.org/10.1016/j.ymgme.2017.09.010

35. Motamed M, Thorne S, Narula A. Treatment of otitis media with effusion in children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2000;53(2):121-124. doi: https://doi.org/10.1016/s0165-5876(00)00320-7

36. Mucopolysaccharidosis Type I. Adam MP, Ardinger HH, Pagon RA, et al., eds. Seattle (WA):University of Washington, Seattle; 19932020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1162. Accessed on September 20, 2022.

37. Congedi S, Orzalesi M, Di Pede C, Benini F. Pain in Mucopolysaccharidoses: Analysis of the Problem and Possible Treatments. Int J Mol Sci. 2018;19(10):3063. doi: https://doi.org/10.3390/ijms19103063

38. Venekamp RP, Hearne BJ, Chandrasekharan D, et al. Tonsillectomy or adenotonsillectomy versus non-surgical management for obstructive sleep-disordered breathing in children. Cochrane Database Syst Rev. 2015;2015(10):CD011165. doi: https://doi.org/10.1002/14651858.CD011165.pub2

39. Yang L, Shan Y, Wang S, et al. Endoscopic assisted adenoidectomy versus conventional curettage adenoidectomy: a meta-analysis of randomized controlled trials. Springerplus. 2016;5:426. doi: https://doi.org/110.1186/s40064-016-2072-1

40. Harrison R, Schaefer S, Warner L, et al. Transnasal adenoidectomy in mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol. 2018;111: 149-152. doi: https://doi.org/10.1016/j.ijporl.2018.04.028

41. Mitchell RB, Archer SM, Ishman SL, et al. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngol Head Neck Surg. 2019;160(1_Suppl):S1-S42. doi: https://doi.org/10.1177/0194599818801757

42. Borg GAV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-381.

43. Borg G. Borg's Perceived Exertion and Pain Scales. USA: Human Kinetics; 1998. p. 2.

44. Grant S, Aitchison T, Henderson E, et al. A comparison of there-producibility and the sensitivity to change of visual analogue scales, Borg scales, and Likertscales in normal subjects during submaxi-mal exercise. Chest. 1999;116(5):1208-1217. doi: https://doi.org/10.1378/chest.116.5.1208

45. Braunlin E, Steinberger J, DeFor T, et al. Metabolic Syndrome and Cardiovascular Risk Factors after Hematopoietic Cell Transplantation in Severe Mucopolysaccharidosis Type I (Hurler Syndrome). Biol Blood Marrow Transplant. 2018;24(6):1289-1293. doi: https://doi.org/10.1016/j.bbmt.2018.01.028